Could an antidepressant ease stubborn back pain?
NCT ID NCT05851976
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether duloxetine, a medication often used for depression, can reduce low back pain in people who didn't get better with NSAIDs like naproxen. About 120 adults from the emergency department will take either duloxetine or a placebo for two weeks. The goal is to see if duloxetine helps prevent ongoing pain three months later.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Duloxetine
- What this could lead to
- If it works, this could offer a new option for people with low back pain who don't get relief from common anti-inflammatory drugs.
- What could go wrong
- This is a small, early-phase exploratory study, so results may not apply widely. Duloxetine can cause side effects like nausea or dizziness, and it may not help everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Present to Emergency Department (ED) primary for management of LBP, defined as pain originating between the lower border of the scapulae and the upper gluteal folds. Flank pain, that is pain originating from tissues lateral to the paraspinal muscles, will not be included. * Musculoskeletal etiology of low back. Patients with non-musculoskeletal etiologies such as urinary tract infection, ovarian cysts, or influenza like illness will be excluded. The primary clinical diagnosis, at the conclusion of the ED visit, must be a diagnosis consistent with non-traumatic, non-radicular, musculoskeletal LBP. * Patient is to be discharged home. Patients admitted to the hospital are more likely to be treated with parenteral medication and therefore are not appropriate for this study. * Age 18-64 Enrollment will be limited to adults younger than 65 years because of the increased risk of adverse medication effects in older patients. * Non-radicular pain. Patients will be excluded if the pain radiates below the gluteal folds in a radicular pattern. * Pain duration \<2 weeks (336 hours). * Prior to the acute attack of LBP, back pain cannot occur more frequently than once per week. * Functionally impairing back pain: A baseline score of \> 5 on the Roland-Morris Disability Questionnaire Exclusion Criteria: * Not available for follow-up * Pregnant or breast-feeding * Chronic pain syndrome defined as moderate or severe pain anywhere in their body on \>= 50% of days for at least three months * Allergic to or intolerant of investigational medications * Contra-indications to non-steroidal anti-inflammatory drugs: 1. history of hypersensitivity to NSAIDs or aspirin 2. active or history of peptic ulcer disease, chronic dyspepsia, or active or history of gastrointestinal bleed 3. Severe heart failure (NYHA 2 or worse) 4. uncontrolled blood pressure (\>160/100) 5. Glomerular Filtration Rate (GFR) \<60ml/min 6. Current use of anti-coagulants 7. cirrhosis or acute hepatitis * Contra-indication to duloxetine: 1. alcohol use disorder 2. chronic liver disease 3. chronic kidney disease 4. glaucoma 5. Active use of medication for depression 6. Score \> 10 on the Patient Health Questionnaire (PHQ-9) screening instrument or thoughts of suicide, symptoms of feeling down, depressed, or hopeless PHQ9 score \>4. Now we would like to exclude patients with a PHQ9 score \>10 or symptoms of feeling down, depressed, or hopeless
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Back pain, low are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study tests drug-free pain relief after back surgery to cut opioid use
- Sports bra study aims to bust pain in Full-Busted women
- Mat exercises vs. mackenzie method: which eases menopause back pain?
- Ear freeze for back pain? scientists scan brain to find out
- New registry follows 500 patients receiving disc injection for back pain
- Could a Physio-First model ease your back pain?